haematology

(redirected from haematological)
Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.
Related to haematological: hematological

haematology

he·ma·tol·o·gy

(hē'mă-tol'ŏ-jē)
The medical specialty that pertains to the anatomy, physiology, pathology, symptomatology, and therapeutics related to the blood and blood-forming tissues.
Synonym(s): haematology.
[hemato- + G. logos, study]

haematology

The study of the blood and blood disorders. The main subjects of concern are the various forms of ANAEMIA, POLYCYTHAEMIA, the HAEMOGLOBINOPATHIES such as SICKLE-CELL DISEASE and THALASSAEMIA, PURPURA, HAEMOPHILIA, clotting disorders and the LEUKAEMIAS. Haematology is also concerned with all aspects of blood transfusion and its complications.

haematology

the study of blood.

he·ma·tol·o·gy

(hē'mă-tol'ŏ-jē)
The medical specialty that pertains to the anatomy, physiology, pathology, symptomatology, and therapeutics related to blood and blood-forming tissues.
Synonym(s): haematology.
[hemato- + G. logos, study]
References in periodicals archive ?
In Cyprus, we have estimated to have around 400-500 new cases of haematological malignancies a year, of which 100 cases include leukaemia with incalculable social and economic impacts".
Thrombocytopenia occurring in this study as the most common haematological alteration may further suggest its diagnostic importance in malaria.
Haematological indices and the prevalence of anaemia in an elderly Chinese population.
The commencement of the Phase II haematology trials follows a number of pre-clinical studies and Phase I trials in which Aplidin(R) demonstrated activity in haematological malignancies as well as a favourable safety profile.
The studies focused on solid tumours will be led by Pharmacyclics, while AstraZeneca will lead those exploring haematological cancers.
Aplidin is already in clinical development in Europe and Canada for the treatment of solid tumours, haematological malignancies and paediatric tumours.
The study will evaluate the combination as a treatment for patients suffering from haematological cancers including diffuse large B-cell lymphoma and follicular lymphoma, which are investigational uses for both compounds.
Haematological toxicities reported in the study have been no higher than Common Toxicity Criteria (CTC) grade 2 (anemia, low lymphocytes, low neutrophils and low leucopenia), with no report of platelet toxicity.
Contract notice: Supply of Haematological material.
Contract notice: Haematological analysis instrument.
Latest results in pre-clinical studies show evidence of the effectiveness of PI-88 in haematological cancer in addition to previously demonstrated efficacy in solid tumours.
Safety data revealed no marked difference between the treatment groups other than the expected side effect of musculoskeletal events with marimastat and haematological events with gemcitabine.